Emerging therapies in castrate-resistant prostate cancer.

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61

Immunotherapy of cancer in 2012. CA Cancer J Clin (2012) 2.12

miR-125b promotes growth of prostate cancer xenograft tumor through targeting pro-apoptotic genes. Prostate (2010) 1.55

Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med (2009) 1.31

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer (2010) 1.18

Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging. Curr Urol Rep (2010) 1.11

Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening. J Med Chem (2011) 1.09

Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One (2013) 1.04

'Image and treat': an individualized approach to urological tumors. Curr Opin Oncol (2010) 1.03

EZH2, an epigenetic driver of prostate cancer. Protein Cell (2013) 1.02

Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00

Cancer vaccine by fusions of dendritic and cancer cells. Clin Dev Immunol (2010) 1.00

Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol Ther (2009) 0.98

Prostate specific membrane antigen- a target for imaging and therapy with radionuclides. Discov Med (2010) 0.97

PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95

Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors. Semin Immunol (2010) 0.95

Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses. Clin Cancer Res (2011) 0.93

Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer. Can Urol Assoc J (2015) 0.92

Redefining hormone resistance in prostate cancer. Ther Adv Med Oncol (2010) 0.91

Epigenetic repression of regulator of G-protein signaling 2 promotes androgen-independent prostate cancer cell growth. Int J Cancer (2011) 0.91

Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res (2011) 0.86

Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation. J Cell Biochem (2014) 0.84

Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells. ACS Chem Biol (2012) 0.83

Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat (2010) 0.82

Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (2010) 0.80

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther (2012) 0.79

Measurement of bone turnover in prostate cancer patients receiving intermittent androgen suppression therapy. Open Access J Urol (2010) 0.77

Type I Collagen Synthesis Marker Procollagen I N-Terminal Peptide (PINP) in Prostate Cancer Patients Undergoing Intermittent Androgen Suppression. Cancers (Basel) (2011) 0.76

Histological changes caused by meclofenamic acid in androgen-independent prostate cancer tumors: evaluation in a mouse model. Int Braz J Urol (2015) 0.75

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93

Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol (2004) 4.25

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol (2011) 2.57

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31

Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience. Radiat Oncol (2013) 2.16

Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int (2010) 2.15

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol (2008) 1.62

Update on castrate-resistant prostate cancer: 2010. Curr Opin Oncol (2010) 1.18

A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer. Technol Cancer Res Treat (2010) 1.07

Attitudes and use of complementary medicine in men with prostate cancer. J Urol (2002) 1.02

Update on hormone-refractory prostate cancer. Curr Opin Urol (2004) 0.95

Low incidence of new biochemical and clinical hypogonadism following hypofractionated stereotactic body radiation therapy (SBRT) monotherapy for low- to intermediate-risk prostate cancer. J Hematol Oncol (2011) 0.94

Importance of serum hemoglobin in hormone refractory prostate cancer. Clin Cancer Res (2002) 0.80

Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives. Future Oncol (2011) 0.78

Targeted therapy in prostate cancer--are we our own worst enemy? Cancer (2008) 0.78

Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma. Cancer (2004) 0.75